Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984750 | 1.00 | SCN9A (0.48) | SCN9AUSP30PARP1PBKHDAC4 | |
| SCHEMBL985086 | 0.97 | SCN9A (0.46) | SCN9AUSP30PARP1PBKHDAC4 | |
| SCHEMBL985727 | 0.97 | SCN9A (0.46) | SCN9AUSP30PARP1PBKHDAC4 | |
| SCHEMBL985085 | 0.97 | SCN9A (0.46) | SCN9AUSP30PARP1PBKHDAC4 | |
| SCHEMBL984128 | 0.96 | USP30 (0.47) | SCN9AUSP30PARP1RIPK1BTK | |
| SCHEMBL984125 | 0.96 | USP30 (0.47) | SCN9AUSP30PARP1RIPK1BTK | |
| SCHEMBL986209 | 0.93 | USP30 (0.47) | SCN9AUSP30PARP1RIPK1BTK | |
| SCHEMBL986210 | 0.93 | USP30 (0.47) | SCN9AUSP30PARP1RIPK1BTK | |
| SCHEMBL984571 | 0.92 | SCN9A (0.42) | SCN9AUSP30PARP1BTK | |
| SCHEMBL982924 | 0.91 | MDM4 (0.36) | SCN9ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | SCN9A 893/4885USP30 2837/4885PARP1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.